Spero Therapeutics (SPRO) shares gained in the premarket on Tuesday after the company announced a $105M financing deal with ...

Initiating high-efficacy monoclonal antibody therapy before age 18 may reduce long-term disability in pediatric-onset multiple sclerosis.

The antibody uses a dual mechanism of action and works to block the interaction between TSLP and its receptor.

Recently validated markers have helped improve treatment but more are needed ...

Dozens of research teams around the world are working to halt, treat and even prevent Alzheimer's disease, which silently ...

Funding will support continued development of Calpurbatug (TRL1068), a novel therapy being evaluated for prosthetic joint infections (PJI) REDWOOD CITY, Calif., July 16, 2026 /PRNewswire/ -- Trellis ...

Eleven new molecular drug targets receive approval in 2025, expanding treatment options for rare diseases, cancer, and infectious diseases.

Is there something to reduce leakage? Is there something in the blood-retinal barrier? Is there something that Ang2 or other ...

Mark Graham shares that the company plans to explore nipocalimab's potential in targeting disease-driving pathways in SLE.

Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarcibart), a novel, Protein S-targeting, ...

KIT-targeting antibody biotech Jasper Therapeutics is being renewed via a merger with Nasdaq-listed Kira Pharmaceuticals—but ...

Greenwich LifeSciences is a single-asset biotech focused on GLSI-100, an immunotherapy for HER2-positive breast cancer. Learn ...